GeneTx and Ultragenyx Announce Presentations at Upcoming 2021 FAST Global Summit & GalaGlobeNewsWire • 12/01/21
Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type IIIGlobeNewsWire • 12/01/21
Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/03/21
Ultragenyx to Host Conference Call for Third Quarter 2021 Financial Results and Corporate UpdateGlobeNewsWire • 10/26/21
Ultragenyx Announces Crysvita® (burosumab) and UX143 (setrusumab) Data Presentations at Upcoming American Society for Bone and Mineral Research (ASBMR) 2021 Annual MeetingGlobeNewsWire • 09/27/21
Long-Term CRYSVITA® ▼ (burosumab) Treatment Reduces the Burden of Disease in Adults With X-Linked Hypophosphataemia (XLH), a Rare Genetic Metabolic Bone DiseaseBusiness Wire • 09/24/21
MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in ItalyGlobeNewsWire • 09/09/21
MEDIA ADVISORY: Ultragenyx Canada Announces Health Canada Approval of a Second Indication for Crysvita™ (Burosumab Injection) for the Treatment of Tumour Induced Osteomalacia in AdultsGlobeNewsWire • 09/07/21
Ultragenyx to Participate in Panel at Citi's 16th Annual BioPharma Healthcare ConferenceGlobeNewsWire • 09/01/21
Ultragenyx (RARE) Up 15% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/01/21
Ultragenyx Announces Approval of Dojolvi® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and ChildrenGlobeNewsWire • 08/23/21
Ultragenyx to Participate in Gene Therapy Panel at Wedbush PacGrow Healthcare ConferenceGlobeNewsWire • 08/04/21
Ultragenyx Pharmaceutical Inc.'s (RARE) CEO Emil Kakkis on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/03/21